COMPASS THERAPEUTICS, INC. Operating Expenses
COMPASS THERAPEUTICS, INC. (CMPX) reported Operating Expenses of $26.98 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2026-08-06
- COMPASS THERAPEUTICS, INC. operating expenses for the quarter ending 2026-06-30 was $26.98M, a 28.07% increase year-over-year.
- COMPASS THERAPEUTICS, INC. operating expenses for the quarter ending 2026-03-31 was $20.30M, a 12.99% increase year-over-year.
- COMPASS THERAPEUTICS, INC. operating expenses for the quarter ending 2025-12-31 was $17.99M, a 8.54% increase year-over-year.
- COMPASS THERAPEUTICS, INC. operating expenses for the quarter ending 2025-09-30 was $15.82M, a 29.23% increase year-over-year.
- COMPASS THERAPEUTICS, INC. operating expenses for fiscal 2025 was $72.84M, a 26.73% increase from fiscal 2024.
- COMPASS THERAPEUTICS, INC. operating expenses for fiscal 2024 was $57.48M, a 14.12% increase from fiscal 2023.
- COMPASS THERAPEUTICS, INC. operating expenses for fiscal 2023 was $50.36M, a 20.91% increase from fiscal 2022.
- COMPASS THERAPEUTICS, INC. operating expenses for fiscal 2022 was $41.66M, a 49.13% decline from fiscal 2021.
| Period end | Operating Expenses 3 month | Operating Expenses 6 month | Operating Expenses 9 month | Operating Expenses 12 month |
|---|---|---|---|---|
| 2026-06-30 | $26.98M 10-Q · filed 2026-08-06 | $47.28M 10-Q · filed 2026-08-06 | $65.27M derived: sum of 3 quarters · filed 2026-08-06 | $81.08M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $20.30M 10-Q · filed 2026-05-05 | $38.29M derived: sum of 2 quarters · filed 2026-05-05 | $54.11M derived: sum of 3 quarters · filed 2026-05-05 | $75.17M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $17.99M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $33.81M derived: sum of 2 quarters · filed 2026-03-05 | $54.87M derived: sum of 3 quarters · filed 2026-08-06 | $72.84M 10-K · filed 2026-03-05 |
| 2025-09-30 | $15.82M 10-Q · filed 2025-11-05 | $36.88M derived: sum of 2 quarters · filed 2026-08-06 | $54.85M 10-Q · filed 2025-11-05 | $71.42M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $21.07M 10-Q · filed 2026-08-06 | $39.03M 10-Q · filed 2026-08-06 | $55.61M derived: sum of 3 quarters · filed 2026-08-06 | $67.84M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $17.97M 10-Q · filed 2026-05-05 | $34.54M derived: sum of 2 quarters · filed 2026-05-05 | $46.78M derived: sum of 3 quarters · filed 2026-05-05 | $62.67M derived: sum of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | $16.57M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $28.81M derived: sum of 2 quarters · filed 2026-03-05 | $44.71M derived: sum of 3 quarters · filed 2026-03-05 | $57.48M 10-K · filed 2026-03-05 |
| 2024-09-30 | $12.24M 10-Q · filed 2025-11-05 | $28.13M derived: sum of 2 quarters · filed 2025-11-05 | $40.90M 10-Q · filed 2025-11-05 | $56.30M derived: sum of 4 quarters · filed 2025-11-05 |
| 2024-06-30 | $15.89M 10-Q · filed 2025-08-11 | $28.66M 10-Q · filed 2025-08-11 | $44.06M derived: sum of 3 quarters · filed 2025-08-11 | $55.98M derived: sum of 4 quarters · filed 2025-08-11 |
| 2024-03-31 | $12.77M 10-Q · filed 2025-05-08 | $28.16M derived: sum of 2 quarters · filed 2025-05-08 | $40.09M derived: sum of 3 quarters · filed 2025-05-08 | $53.43M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | $15.39M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $27.32M derived: sum of 2 quarters · filed 2025-02-27 | $40.66M derived: sum of 3 quarters · filed 2025-02-27 | $50.36M 10-K · filed 2025-02-27 |
| 2023-09-30 | $11.93M 10-Q · filed 2024-11-12 | $25.26M derived: sum of 2 quarters · filed 2024-11-12 | $34.97M 10-Q · filed 2024-11-12 | $47.86M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | $13.34M 10-Q · filed 2024-08-12 | $23.05M 10-Q · filed 2024-08-12 | $35.94M derived: sum of 3 quarters · filed 2024-08-12 | $48.53M derived: sum of 4 quarters · filed 2024-08-12 |
| 2023-03-31 | $9.71M 10-Q · filed 2024-05-13 | $22.60M derived: sum of 2 quarters · filed 2024-05-13 | $35.20M derived: sum of 3 quarters · filed 2024-05-13 | $44.18M derived: sum of 4 quarters · filed 2024-05-13 |
| 2022-12-31 | $12.89M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21 | $25.49M derived: sum of 2 quarters · filed 2024-03-21 | $34.47M derived: sum of 3 quarters · filed 2024-03-21 | $41.66M 10-K · filed 2024-03-21 |
| 2022-09-30 | $12.60M 10-Q · filed 2023-11-09 | $21.59M derived: sum of 2 quarters · filed 2023-11-09 | $28.77M 10-Q · filed 2023-11-09 | $41.77M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $8.99M 10-Q · filed 2023-08-03 | $16.17M 10-Q · filed 2023-08-03 | $29.17M derived: sum of 3 quarters · filed 2023-08-03 | $35.02M derived: sum of 4 quarters · filed 2023-08-03 |
| 2022-03-31 | $7.18M 10-Q · filed 2023-05-04 | $20.18M derived: sum of 2 quarters · filed 2023-05-04 | $26.04M derived: sum of 3 quarters · filed 2023-05-04 | $81.73M derived: sum of 4 quarters · filed 2023-05-04 |
| 2021-12-31 | $13.00M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-15 | $18.86M derived: sum of 2 quarters · filed 2023-03-15 | $74.54M derived: sum of 3 quarters · filed 2023-03-15 | $81.88M 10-K · filed 2023-03-15 |
| 2021-09-30 | $5.85M 10-Q · filed 2022-11-09 | $61.54M derived: sum of 2 quarters · filed 2022-11-09 | $68.88M 10-Q · filed 2022-11-09 | $76.83M derived: sum of 4 quarters · filed 2022-11-09 |
| 2021-06-30 | $55.69M 10-Q · filed 2022-08-01 | $63.02M 10-Q · filed 2022-08-01 | $70.98M derived: sum of 3 quarters · filed 2022-08-01 | $79.94M derived: sum of 4 quarters · filed 2022-08-01 |
| 2021-03-31 | $7.34M 10-Q · filed 2022-05-09 | $15.29M derived: sum of 2 quarters · filed 2022-05-09 | $24.25M derived: sum of 3 quarters · filed 2022-05-09 | $29.32M derived: sum of 4 quarters · filed 2022-05-09 |
| 2020-12-31 | $7.95M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-18 | $16.91M derived: sum of 2 quarters · filed 2022-03-18 | $21.98M derived: sum of 3 quarters · filed 2022-03-18 | $27.81M 10-K · filed 2022-03-18 |
| 2020-09-30 | $8.96M 10-Q · filed 2021-11-12 | $14.03M derived: sum of 2 quarters · filed 2021-11-12 | $19.86M 10-Q · filed 2021-11-12 | $26.26M derived: sum of 4 quarters · filed 2021-11-12 |
| 2020-06-30 | $5.07M 10-Q · filed 2021-08-16 | $10.90M 10-Q · filed 2021-08-16 | $17.30M derived: sum of 3 quarters · filed 2021-08-16 | $25.69M derived: sum of 4 quarters · filed 2021-08-16 |
| 2020-03-31 | $5.83M 10-Q · filed 2021-04-30 | $12.23M derived: sum of 2 quarters · filed 2021-04-30 | $20.62M derived: sum of 3 quarters · filed 2021-04-30 | $29.29M derived: sum of 4 quarters · filed 2021-04-30 |
| 2019-12-31 | $6.40M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-05 | $14.79M derived: sum of 2 quarters · filed 2021-03-05 | $23.46M derived: sum of 3 quarters · filed 2021-03-05 | $34.05M 10-K · filed 2021-03-05 |
| 2019-09-30 | $8.38M 10-Q · filed 2020-11-09 | $17.06M derived: sum of 2 quarters · filed 2020-11-09 | $27.65M 10-Q · filed 2020-11-09 | |
| 2019-06-30 | $8.67M 10-Q · filed 2020-08-13 | $19.27M 10-Q · filed 2020-08-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Protara Therapeutics, Inc. (TARA) | United States | $0.198B | -3.22 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |